Skip to search formSkip to main contentSkip to account menu

smelt allergenic extract 50 MG/ML Injectable Solution

Known as: SMELT 0.05 g in 1 mL INTRADERMAL INJECTION, SOLUTION, SMELT 0.05 g in 1 mL SUBCUTANEOUS INJECTION, SOLUTION, smelt allergenic extract 0.05 GM/ML Injectable Solution 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
chronic venous thromboses were also more common than acute thrombosis. Squizzato et al.1 reported 13 cases of acute cerebral… 
Review
2016
Review
2016
Introduction Our hospice has provided a horticultural therapy group which is open to in- and out- patients since February 2016… 
2011
2011
The invention discloses a method for the leaching of manganese from manganese-containing smelt flue dust, comprising the… 
2010
2010
The smelt project is part of a larger research project that aims at generating, exploring and testing different possible… 
1999
1999
...............................................................................................................................................................................3 INTRODUCTION .........................................................................................................................................................................4 INTERVENTION STUDIES............................................................................................................................................................5 Angiographic studies............................................................................................................................................................5 Dietary intervention studies .................................................................................................................................................5 Statin intervention studies....................................................................................................................................................6 GUIDELINES BASED ON LITERATURE DATA ...............................................................................................................................7 Secondary prevention...........................................................................................................................................................7 Primary prevention ..............................................................................................................................................................8 Cost-effectiveness.................................................................................................................................................................9 CONCLUSION ..........................................................................................................................................................................10 GUIDELINES AND COST........................................................................................................13 ABSTRACT ..............................................................................................................................................................................13.............................................................................................................................................................................13 INTRODUCTION .......................................................................................................................................................................13 THE BALANCE BETWEEN COSTS AND EFFECTS .......................................................................................................................13 WHO DECIDES? .......................................................................................................................................................................14 THE CONSENSUS GUIDELINE ..................................................................................................................................................15 LIMITATIONS OF COST-EFFECTIVENESS ANALYSES ................................................................................................................17 CONCLUSION ..........................................................................................................................................................................19 WORKING GROUP..................................................................................................................21 REFERENCES.........................................................................................................................22 
1994
1994
This paper describes an improved model of char burning during black liquor combustion that is capable of predicting net rates of…